Villejuif

• Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Ended
  2024-514570-43-00 5 2022-01-24 Renal cell carcinoma
• Study comparing the standard administration of immunotherapy (IO) versus the same agent administered each three months in patients with loca … Ended
  2024-513707-14-00 5 2022-01-14 Only patients with oncologic locally advanced or metastatic tumour (lu
• A study to assess the effect of CC-95251 alone and in combination with anti-cancer drugs in subjects with Acute Myeloid Leukemia and Myelody … Ended
  2023-506117-22-00 3 2022-01-05 Acute Myeloid Leukemia and Myelodysplastic Syndromes
• GEN1047 for Solid Tumors - First in Human (FIH) Trial Ended
  2024-510722-10-00 7 2021-12-13 Malignant Solid Tumors
• Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III … Ended
  2023-507688-20-00 5 2021-12-03 Participants with completely resected Stage III or Stage IV melanoma
• Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Ended
  2023-510511-19-00 7 2021-11-08 Advanced Solid Tumors
• A study to assess the safety and efficacy of AZD7789 in participants with advanced or metastatic solid cancer Ended
  2022-502774-17-00 7 2021-10-04 Advanced or metastatic gastric and gastro-esophageal junction (GEJ) ad
• A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical Cancer Ended
  2023-503813-31-01 5 2021-09-17 Second- or Third-Line Recurrent or Metastatic Cervical Cancer
• 7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors Ended
  2023-505284-36-00 4 2021-09-13 Advanced solid tumors
• First-in-Human Study of RLY-4008 in Patients With ICC and Other Advanced Solid Tumors Ended
  2024-512622-29-00 7 2021-09-10 Cholangiocarcinoma (CCA) and Other Advanced Solid Tumors
• A study of PRS-344/S095012 (PD-L1x4-1BB bispecific antibody) in patients with solid tumors Ended
  2023-510046-25-00 7 2021-09-02 Soild Tumors
• Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) Ended
  2024-511728-15-00 7 2021-08-26 Solid tumors
• A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B cell Non-Hodgkin Lymphoma and … Ended
  2024-512689-32-00 3 2021-07-15 Non-Hodgkin lymphoma and chronic lymphocytic leukemia
• A Dose Finding Phase 1 Study of CC-96191 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia Ended
  2022-500573-13-00 1 2021-07-06 Relapsed or Refractory Acute Myeloid Leukemia
• A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Local … Ended
  2024-513870-23-00 5 2021-06-28 Locally Advanced or Metastatic Unresectable Urothelial Cancer
• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain M … Ended
  2023-506315-17-00 9 2021-06-25 Advanced melanoma with brain metastases, PD-1 refractory or PD-1 naiv
• A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma Ended
  2023-503280-42-00 5 2021-06-01 Metastatic Clear Cell Renal Cell Carcinoma
• A Phase 1b Study of AMG 757 in Subjects with Neuroendocrine Prostate Cancer Ended
  2024-513316-10-00 3 2021-04-20 Adult subjects with de novo or treatment-emergent neuroendocrine prost
• MK-7684A (new drug co-formulation of pembrolizumab with an anti-TIGIT) plus docetaxel works to help stop or slow down the growth of your non … Ended
  2022-501252-28-00 4 2021-04-15 Non Small Cell Lung cancer
• A first-in-human clinical trial in adult patients with advanced non-small cell lung cancer of a personalised therapy targeting specific muta … Ended
  2024-513060-26-00 7 2021-04-07 Non-small cell lung cancer
• RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in pa … Ended
  2024-513982-38-00 5 2021-03-17 Metastatic or unresectable advanced rare sarcomas
• “A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatini … Ended
  2023-508001-25-00 4 2021-03-15 Metastatic Thymic Carcinoma & B3-thymoma.
• A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors Ended
  2024-518529-14-00 7 2021-02-26 Metastatic/advanced soft tissue sarcoma (STS), Merkel cell carcinoma (
• Phase I/II trial of S65487 plus azacitidine in acute myeloid leukemia Ended
  2023-510051-27-00 7 2021-02-25 Acute Myeloid Leukemia (AML)

Showing 865–888 of 961 trials